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Electrochemotherapy has a direct cytotoxic effect on tumour cells, and presumably, a vascular disrupting effect. In this study, on the
basis of the prediction of the mathematical model, histological evaluation and physiological measurements of the tumours were
carried out to confirm that electroporation and electrochemotherapy of tumours have a vascular disrupting action. In the study, SA-1
solid subcutaneous sarcoma tumours in A/J mice were treated by bleomycin (BLM) given intravenously (1mgkg
 1), application of
electric pulses (8 pulses, 1040V, 100ms, 1Hz) or a combination of both – electrochemotherapy. The vascular effect was determined
by laser Doppler flowmetry, power Doppler ultrasonographic imaging and Patent blue staining. The extent of tumour hypoxia was
determined immunohistochemically by hypoxia marker pimonidazole and partial pressure of oxygen (pO2) in tumours by electron
paramagnetic resonance oximetry. Electrochemotherapy with BLM induced good antitumour effect with 22 days, tumour growth
delay and 38% tumour cures. The application of electric pulses to the tumours induced instant but transient tumour blood flow
reduction (for 70%) that was recovered in 24h. During this tumour blood flow reduction, we determined an increase in hypoxic
tumour area for up to 30%, which was also reflected in reduced tumour oxygenation (for 70%). According to the described
mathematical model, endothelial cells lining in tumour blood vessels are exposed to a B40% higher electric field than the surrounding
tumour cells, and therefore easily electroporated, allowing access of high BLM concentration to the cytosol. Consequently,
electrochemotherapy has, besides the immediate vascular disrupting action, also a delayed one (after 24h), as a consequence of
endothelial cell swelling and apoptosis demonstrated by extensive tumour necrosis, tumour hypoxia, prolonged reduction of tumour
blood flow and significant tumour growth delay, and tumour cures. Our results demonstrate that in addition to the well-established
direct cytotoxic effect on tumour cells, electrochemotherapy also has an indirect vascular disrupting action resulting altogether in
extensive tumour cell necrosis leading to complete regression of tumours.
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In vivo electroporation has found its place as a drug delivery
system for chemotherapeutics, that is electrochemotherapy, and is
currently under intensive investigation for delivery of therapeutic
genes to normal tissues and tumours, that is gene electrotransfer
(Neumann et al, 1982; Cemazar et al, 2006; Heller and Heller, 2006;
Mir, 2006). Bleomycin (BLM) and cisplatin proved to be effective
in electrochemotherapy for treatment of various tumours in mice,
rats, cats, dogs and horses (Sersa et al, 2006b). In a clinical setting,
several studies predominantly on patients with malignant mela-
noma, basal cell carcinoma, head and neck tumours, and others
have proved antitumour effectiveness of electrochemotherapy by
long-lasting local tumour control (Heller et al, 1999; Marty et al,
2006; Sersa, 2006a).
The predominant underlying mechanism of electrochemo-
therapy is electroporation of cells in the tissues, which facilitates
access of poorly permeant and nonpermeant molecules, including
cytotoxic drugs such as BLM and cisplatin, into the cells (Mir,
2006). In addition to electroporation of tumour cells, electric
pulses were found to modify blood flow in normal tissues and in
tumours (Ramirez et al, 1998; Sersa et al, 1998, 1999b; Engstrom
et al, 2001; Gehl et al, 2002). This phenomenon was well
documented by different techniques demonstrating reduced blood
flow and oxygenation in the tumours (Sersa et al, 1999b, 2002). In
addition, we demonstrated that electroporation of adherent
endothelial monolayer induced disruption of actin filaments and
microtubule network cytoskeleton as well as loss of cell–cell
contact junctions, which altogether increased endothelial mono-
layer permeability (Kanthou et al, 2006). This suggests that in
addition to the direct effect of electric pulses applied to the
tumour, there may also be an indirect effect on tumour via the
effect of electric pulses on tumour blood vessels (vascular
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sdisrupting effect). Furthermore, we have previously demonstrated
that electrochemotherapy with either BLM or cisplatin also has a
tumour blood flow modifying effect (Sersa et al, 1999a, 2002). In
addition, we showed that cultured endothelial cells are very
susceptible to electrochemotherapy with BLM and to the same
extent as tumour cells in the case of electrochemotherapy with
cisplatin (Cemazar et al, 2001). Therefore, by electroporation of
endothelial cells in tumour blood vessels, these may also become
susceptible to chemotherapeutics, leading to endothelial cell death,
vessel occlusion and abrogated tumour blood flow, thus inducing a
cascade of cell death in the surroundings of the occluded blood
vessel. If so, then electrochemotherapy is also currently a member
of the intensively investigated vascular disrupting therapies that
cause a rapid and selective shutdown of established tumour
vasculature and can lead to secondary tumour cell death (Tozer
et al, 2001, 2005; Siemann et al, 2005).
In this study, we present a mathematical model of electric field
distribution in tumour blood vessels, predicting vascular disrup-
ting action of electrochemotherapy. The prediction of the model is
supported by the data demonstrating reduced tumour blood flow
after electroporation and electrochemotherapy with BLM as well
as pronounced tumour hypoxia, reduced tumour oxygenation,
endothelial cells swelling and apoptosis, and extensive tumour cell
necrosis. The study demonstrates that in addition to the direct
effect on tumour cells, electrochemotherapy also has a vascular
disrupting effect.
MATERIALS AND METHODS
Mice and tumours
Murine fibrosarcoma SA-1 (The Jackson Laboratory, Bar Harbor,
ME, USA) cells were used in the experiments. A/J mice of both
sexes, purchased from the Institute of Pathology, Faculty of
Medicine, University of Ljubljana, Slovenia, were used for this
study. They were kept at a constant room temperature (221C) with
a natural day/night light cycle in a conventional animal colony
with food and water ad libitum. Before the experiments, the mice
were subjected to an adaptation period of at least 10 days. The
mice were 10–14 weeks old at the beginning of the experiments,
weighing 20–25g.
Tumour cells were obtained from the ascitic form of the
tumours in mice. Solid subcutaneous tumours, located dorso-
laterally in mice, were initiated by an injection of 5 10
5 SA-1 cells
in 0.1ml 0.9% NaCl solution. Six to 8 days after implantation,
when tumours reached approximately 40mm
3 in volume, the mice
were randomly divided into experimental groups. The study was
approved by the Ministry of Agriculture, Forestry and Food of the
Republic of Slovenia (No. 323-02-237/01) in compliance with the
Guide for the Care and Use of Laboratory Animals (National
Institutes of Health, Bethesda, MD, USA).
Electrochemotherapy
Bleomycin (Heinrich Mack Nachf., Illertissen, Germany) at a dose
of 1mgkg
 1 (B20mg per mouse) was injected intravenously.
Injection volume was 7.5ml per kg body weight. Eight square wave
electric pulses in two sets of four pulses, in two mutually
perpendicular directions of 1040V (at voltage to distance ratio
1300Vcm
 1) and with a pulse duration of 100ms and repetition
frequency of 1Hz, were delivered by two flat, parallel stainless-
steel electrodes 8mm apart (two stainless-steel strips: length
15mm, width 7mm, with rounded corners), which were placed
percutaneously at the opposite margins of the tumour. Good
contact between the electrodes and the skin was assured by means
of a conductive gel. Electric pulses were generated by a Jouan
GHT 1287 electroporator (Jouan, Saint Herblain, France). In the
electrochemotherapy protocol, the mice were treated with electric
pulses 3min after BLM injection. All treatments except in the case
of electron paramagnetic resonance (EPR) oximetry, laser Doppler
measurements and power Doppler ultrasonographic imaging (see
below), were performed without anaesthesia and were well
tolerated by the animals.
Tumour growth was followed by measuring three mutually
orthogonal tumour diameters (e1, e2 and e3) with a Vernier calliper
three times per week. Tumour volumes were calculated according
to the formula for the volume of an ellipsoid, V¼pe1e2e3 6
 1.
The AM (arithmetic mean) of tumour volumes and s.e. were
calculated for each experimental group. Tumour doubling time
was determined for each individual tumour from the growth
curves. Tumour growth delay was calculated for each individual
tumour by subtracting the doubling time of each tumour from the
mean doubling time of the control group and then averaged for
each experimental group. Animals that were tumour free for 100
days were declared cured.
Histology
At different time points after treatment with BLM, the application
of electric pulses and electrochemotherapy of tumour’s morpho-
logical changes, extent of tumour necrosis and the area with
hypoxia marker pimonidazole adduct staining were determined.
Tumour cell and blood vessels morphology as well as the extent of
tumour necrosis were estimated on haematoxylin and eosin-
stained slides. For necrotic tumour area analysis, the slides of three
tumours per group were examined by two co-authors blinded to
therapy status. The area of tumour necrosis was determined in a
whole mount tumour section through the largest tumour diameter
and expressed as a percentage of necrosis in relation to the whole
tumour cross-section area. If the difference between two observers
were greater than 10%, a consensus was achieved.
The hypoxia marker pimonidazole (Hypoxyprobet-1, Natural
Pharmacia International Inc., Belmont, MA, USA) (60mgkg
 1 in
0.2ml PBS) was injected intraperitoneally. Tumours (3–9 per
group) were excised 90min thereafter, fixed in 10% buffered
neutral formalin, embedded in paraffin, cut at three different levels
throughout the tumour and stained for pimonidazole according to
the manufacturer’s instructions. Briefly, the sections were depar-
affinised with xylene and rehydrated in ethanol. Sections were
exposed to 3% H2O2 in methanol for 5min to quench endogenous
peroxidase activity. Antigen retrieval was achieved by incubating
tissue sections with 0.01% pronase for 25min at 401C. Sections
were then incubated with 1:50 dilution of monoclonal anti-
pimonidazole antibody (Natural Pharmacia International Inc.)
for 40min at room temperature. This step was followed by
biotin-conjugated rabbit anti-mouse secondary antibody and
peroxidase-conjugated avidin–biotin complex (Dako, Glostrup,
Denmark). Finally, sections were incubated with 3,30-diamino-
benzidine peroxidase substrate and stained with haematoxylin. The
slide in which primary antibody was omitted served as a negative
control. The mean percentage of area positive for pimonidazole
adducts was determined by the image-based analysis system LUCIA
(Nikon, Tokyo, Japan). The results of the percentages of necrotic
tumour area and the percentages of pimonidazole-positive area
were presented as AM and s.e. for each experimental group.
Mathematical model of electric field distribution in and
around a blood vessel
The lumen of a tumour blood vessel was modelled as a cylinder
with a diameter of 15 and 8mm and an electric conductivity of
0.75Sm
 1 for larger tumour vessels and 0.6Sm
 1 for tumour
capillaries, which is the electric conductivity of the blood serum
(Hirsch et al, 1950, Tozer et al, 2001). The wall of the blood vessel
was modelled as a layer with a thickness of 1mm and the tumour
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stissue as a homogeneous material surrounding the vessel wall.
Both regions were assigned an electric conductivity of 0.3Sm
 1,
which is an average value of reported bulk electric conductivities
of soft tissues (including epithelial and tumour tissues) that range
from 0.1 to 0.5Sm
 1 (Geddes and Barker, 1967; Duck, 1990;
Gabriel et al, 1996). The distribution of the electric potential was
derived analytically by solving the Laplace equation in cylindrical
coordinates with the boundary conditions of homogeneity of the
electric field far from the vessel, boundedness and continuity of the
electric potential, and continuity of the electric current density
(Kotnik et al, 1997; Kotnik and Miklavcic, 2000). The distribution
of the electric field was then determined by calculating the gradient
of the electric potential.
Power Doppler ultrasonographic imaging
The gross tumour perfusion changes after application of electric
pulses, BLM and electrochemotherapy to the tumours were
evaluated by power Doppler ultrasonographic imaging. Before
and after (at 3min, 35min and 48h) different therapies, grey-scale
ultrasound (US) of tumours was performed. The longest and the
shortest diameter of tumour and the longest diameter of an
echogenic central part (necrosis) were measured. After baseline,
US scan evaluation power Doppler US was performed at each time
point to check vascularisation. Before microbubble contrast agent
(Sono Vue, Bracco, Milan, Italy) injection, the persistence of the
image display on the US machine was set to zero, the signal gain
was registered below the noise threshold, and one focus was
positioned below the level of the lesion. SonoVue is a sulphur
hexafluoride-filled microbubble contrast agent that is licensed for
use in abdominal and vascular imaging in most European
countries. This agent has a strong nonlinear harmonic response
when it is insonated with low acoustic power. The safety and
effectiveness of this agent in vascular and parenchymal diagnostic
applications have been proved in preliminary experimental and
clinical investigations (Delorme and Krix, 2006).
SonoVue (5mgml
 1) was mixed with a solution of sodium
chloride 0.9% wv
 1 solution to form a dispersion containing
millions of tiny bubbles of sulphur hexafluoride gas. The solution
was injected intravenously (0.2ml) in mice by using a 27-gauge
needle. After 5–10s, we observed strong peripheral enhancement,
and central necrosis was better depicted as on baseline US image.
If contrast enhancement was considered inadequate by the on-site
examinator after the first bolus injection, the mouse received
an additional microbubble contrast agent bolus (0.2ml). We
monitored contrast enhancement for at least 5min after injection.
During the measurements, the mice were anaesthetised in the same
way as for EPR oximetry measurements. All US examinations were
performed by one experienced radiologist on a US machine (Aplio
HU 80; Toshiba, Otawara, Japan) with a 12MHz, 38-mm long
linear transducer. The scanning plane was selected for optimal
visualisation of enhancement. Dynamic US data were stored in the
US unit until the signal enhancement had completely diminished,
usually within 5min. Static images were obtained before and every
15s after injection of the contrast agent. The whole examination
was stored on a CD for further analysis.
Laser Doppler flowmetry
Relative blood perfusion was monitored using an OxyFlo2000
Laser Doppler flowmeter and OxyData data acquisition unit
(Oxford Optronix Ltd, Oxford, UK). The signals were sampled
and stored at a frequency of 100Hz. The theory and applications
of laser Doppler flowmetry (LDF) are well known (Shepherd and
Oberg, 1990); briefly, LDF measures the spread of the wavelengths
of photons emitted by a coherent laser source when the photons
scatter on moving red blood cells in capillaries. The distribution of
photon wavelengths is used for calculation of relative micro-
circulation in tissue.
For skin measurements, LDF can be used entirely noninvasively.
In our study, we, however, used thin invasive probes (diameter
200mm) to assess the perfusion inside the tumour (Jarm et al,
2002). To minimise discomfort of the mice and to keep them as
motionless as possible during 1h continuous monitoring, the mice
were anaesthetised using isoflurane (flurane-isoflurane; Abbott
Labs, Berkshire, UK). Isoflurane was delivered to the mice via a
miniature face mask in a mixture of oxygen and nitrous oxide
(flow of each 0.6lmin
 1) at 3.0 and 1.8% concentrations,
respectively, for induction and maintenance of anaesthesia.
Although anaesthetised, the mice were kept on an automatically
regulated heating pad to prevent hypothermia. Rectal temperature
was kept as close as possible to 371C with variations of up to
0.51C during single measurements and with the contact surface
temperature of the heating pad always below 391C.
Approximately 4min after the induction of anaesthesia, the data
acquisition was started and a probe inserted in the tumour. The
probe was inserted through a small superficial incision in the
skin, pushed a few millimetres into the tumour and then slightly
withdrawn to minimise the pressure of the tip of the probe on the
surrounding tissue. After approximately 30min, either BLM or
physiological saline was injected intravenously. Exactly 3min after
the injection, the electrodes were attached to the tumour and the
electric pulses delivered. The electrodes were then removed and
the blood flow signal recording continued for at least 1h
afterwards. In the control and BLM groups, the electrodes were
manipulated in the same way as in the groups treated by electric
pulses or electrochemotherapy, except that no electric pulses were
applied. Special care was taken throughout the measurements to
minimise all movements of the probes and the mouse to keep the
movement artefacts in recorded signals as small as possible.
After the measurement, the raw laser Doppler signals were first
filtered using a special custom-made digital filter to remove
movement artefacts caused mostly by respiration of the mice (see
Figure 5A as an example), thus resulting in a smoothed and
downsampled (1Hz) version of the raw signal, which represented
the actual baseline blood flow level. We defined the moment 1sec
before the application of the first electric pulse (3min after
injection) as time zero (see Figure 5B). From the filtered signal,
average blood flow values at distinct predefined time moments
before, at and after the treatment were calculated. In general, these
time moments were spaced at intervals of 5min except around
time zero, where they were distributed more densely to track rapid
changes in baseline blood flow levels occurring after the treatment.
Average blood flow values were calculated from filtered signal
segments of 20s length cantered at the aforementioned time
moments. As the last step, all average blood flow values were
normalised with respect to the average blood flow level measured
5min before time zero (pretreatment value at  5min in Figure 5B
and C). Thus, the blood flow level in each tumour was expressed as
a percentage of the pretreatment blood flow level. These relative
values were then used to present the final results and to evaluate
the effects of different treatments on tumour blood flow.
Assessment of tumour perfusion by Patent blue staining
Patent blue (Byk Gulden, Krenzlingen, Switzerland) was used to
estimate tumour perfusion. Patent blue (1.25%) diluted in 0.2ml
0.9% NaCl was injected at different time points after treatment into
the tail vein of animals with tumours from the control, electric
pulses, BLM and electrochemotherapy groups. After the dye was
distributed evenly through the tissue (1min), animals were killed
and the tumours carefully excised. The excised tumours were
removed from the skin, cut in half along their largest diameter and
photographed. The images were evaluated using Image J software.
The stained area of tumour cross-section was used as an indicator
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sof tumour perfusion. In the study comparing Patent blue staining
and the pharmacological method measuring the relative tumour
blood flow, a good correlation (r¼0.962) was found between both
methods (Sersa et al, 1999a,b).
Electron paramagnetic resonance oximetry
Electron paramagnetic resonance (EPR) oximetry was used to
evaluate changes in the partial pressure of oxygen (pO2)i n
tumours and subcutaneous tissue on the contralateral side before
and after treatment of tumours with electric pulses, BLM and
electrochemotherapy. Electron paramagnetic resonance oximetry
is a non-invasive method (after insertion of the paramagnetic
probe), which allows monitoring of pO2 repeatedly at the same
point in the tissue over long periods of time (O’Hara et al, 2001;
Sersa et al, 2002). For this purpose, a paramagnetic probe, a char
(B0.5mm
3, with particle size of approximately 10mm) from
Bubinga tree (a kind gift of EPR Center for Viable System,
Dartmouth College of Medicine, Hanover, NH, USA), which is
sensitive to oxygen, was implanted into the tumour centre and
periphery (tumour volume approximately 40mm
3) and in the
subcutis 1 day before the treatments. Its EPR spectral linewidth
was measured at different time points up to 2 days after the
treatment. The char implantation with a sterile needle did not
provoke bleeding. In the presence of oxygen, the linewidth of the
EPR lines is broadened; the extent of broadening depends on pO2
(Swartz et al, 1993; Swartz and Clarkson, 1998). The pO2 in the
region in contact with the probe was measured.
The measurements were performed on a Varian E-9 EPR
spectrometer with a custom-made low-frequency microwave
bridge operating at 1.1GHz and an extended loop resonator
(11mm in diameter), both designed by Professor T Walczak
(Dartmouth College of Medicine, Hanover, NH, USA). Typical
spectrometer settings were modulation frequency, 100kHz;
modulation amplitude not more than one-third of the peak-to-
peak linewidth, and scan range, 2mT. The linewidth of the EPR
spectra reflects the pO2, which was determined from an existing
calibration curve (Krzic et al, 2001).
For EPR oximetry, animals were anaesthetised with a mixture of
Domitor (1.0mg per kg body weight; Pfizer GmbH, Karlsruhe,
Germany) and 10% ketamine (75.0mg per kg body weight; Veyx-
Pharma GmbH, Schwarzenborn, Germany) administered intra-
peritoneally. During anaesthesia, body temperature was kept at
physiological values by a regulated heating pad on which the mice
were placed (Guymar T/pump; Linton Instruments, Norfolk, UK).
Statistical analysis
Significance tests were carried out on the data groups using
analysis of variance followed by the Bonferroni t-test for individual
pairwise comparisons, with values of Po0.05 considered as
significant. The SigmaStat statistical software was used for
statistical analysis (SPSS Inc., Chicago, IL, USA).
RESULTS
Antitumour effect of electrochemotherapy
Electrochemotherapy with BLM was very effective in treatment
of subcutaneous SA-1 tumours, resulting in substantial tumour
growth delay and high percentage of tumour cures, compared to
untreated tumours and tumours treated with BLM or application
of electric pulses alone (Table 1).
Tumour histology after electrochemotherapy
Electrochemotherapy with BLM had, as already mentioned,
significant antitumour effect on tumour growth. We specifically
observed significant increase in extent in tumour necrosis reaching
B50% at 48h after the treatment (Po0.05 compared to other
treatment groups). The necrotic areas were found mostly in the
centre of the tumours and consisted of cells with eosinophilic
cytoplasm and pycnotic nuclei. In some cells, acute cellular
swelling and nuclear disappearance with cell ghosts were also
found. Central necrosis was surrounded by a thin viable tumour
rim that led to regrowth after 8–10 days in those tumours that
were not cured (Figure 1). The extent of tumour necrosis in the
tumours treated with BLM only was the same as in the untreated
tumours, confirming the data on tumour growth. The application
of electric pulses alone increased the extent of necrosis in the
tumours, but only transiently, returning to the normal values
within 48h after treatment. This small but significant increase
(Po0.05) in the extent of tumour necrosis up to 24h after the
treatment confirmed the previous observation that the application
of electric pulses alone to the tumours induced a small but
insignificant retardation in tumour growth (tumour growth
delay¼0.6 days, P40.05).
Table 1 Tumour growth after electrochemotherapy with bleomycin
Group N
Tumour doubling time
(days; AM±s.e.)
P-value compared to tumour
doubling time of control
Tumour growth delay
(days; AM±s.e.)
Cures n
(%)
Control 16 1.2±0.06 0
Bleomycin
a 16 1.2±0.04 NS 0.0 0
Electric pulses
b 16 1.8±0.02 NS 0.6±0.02 0
Electrochemotherapy
c 16 23.7±4.6 Po0.05 22.5±4.6 6 (38)
NS¼nonsignificant.
aBleomycin injected intravenously (1mgkg
 1).
bApplication of electric pulses to the tumour (8 pulses, 1040V, 100ms, 1Hz).
cElectrochemotherapy:
application of electric pulses to the tumour 3min after intravenous injection of bleomycin.
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Figure 1 Time course of changes in tumour necrosis in untreated
control tumours, and after treatment of tumours with bleomycin,
application of electric pulses or electrochemotherapy. Symbols indicate
AM (arithmetic mean)±s.e. of at least three mice per point.
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sTumour slides were also examined for blood vessels changes.
Changes in the endothelial cell shape were observed 1h after the
application of electric pulses. Endothelial cells were rounded up
and swollen and the lumen of blood vessels was narrowed
(Figure 2A). After electrochemotherapy, the same morphological
changes were found. At later times after electrochemotherapy (8h),
in some vessels endothelial cells with apoptotic morphological
characteristics were found (Figure 2B). Furthermore, blood vessels
were stacked with erythrocytes and extravasation of erythrocytes
was also observed (Figure 2B). Apoptotic endothelial cells were not
observed in tumours treated with electric pulses alone, BLM alone
or in the control group.
Mathematical model of electric field distribution in and
around a blood vessel
The local distortion of the electric field in the vicinity of a blood
vessel is illustrated in the two plots in Figure 3, for a thin capillary
of 8mm diameter (Figure 3A) and for a thicker tumour vessel of
15mm diameter (Figure 3B). Denoting by E the local field and by E0
the homogeneous field far from the vessel, the plots show the ratio
E/E0 along the cross-section passing through the centre of the
vessel (line a) for the vessel perpendicular to the field direction
and for the vessel tilted by 301 and 601 with respect to the field
direction. As the plots show, the electric field in the tissue at the
very edge of the lumen, that is in the endothelium of the blood
vessel, can exceed the homogeneous value by as much as 42% in
the extreme case (the larger vessel, perpendicular orientation) and
by 10–30% in typical cases, represented by different orientations
of the vessels. This is the consequence of the significantly higher
conductivity of the blood with respect to the surrounding tissue
(see Materials and methods), due to which the electric current is
locally concentrated in the vicinity and inside the blood vessel. In
the blood, the electric field is only 60–90% of the homogeneous
field in the tissue, which reflects the fact that the electric field is the
ratio between the current density and the conductivity and that the
50 m 50 m
AB
Figure 2 (A) Rounding up of tumour blood vessels endothelial cells 1h after electric pulses increases vascular resistance to blood flow (arrows).
(B) Apoptotic-like endothelial cells occur in tumours 8h after electrochemotherapy (arrows).
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Figure 3 The electric field strength in a capillary of 8mm diameter (A), a vessel of 15mm diameter (B) and in the endothelial and tumour tissue
surrounding them. The plot shows the ratio between the local electric field (E) along the line a and the external field to which the tissue is exposed (E0), for
three different orientations of the vessel with respect to the field (901 – solid, 601 – dashed, 301 – dotted). The conductivities of the tissues and the blood
are taken from the literature (Hirsch et al, 1950; Duck 1990; Gabriel et al, 1996). In the capillary, a somewhat lower serum content (and therefore
conductivity) is assumed due to the erythrocytes filling most of the volume in the thin passages.
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sconductivity of blood is considerably higher than the conductivity
of the surrounding tissue. Consequently, the model predicts that
endothelial cells lining the blood vessels are exposed to up to 40%
higher electric field than the surrounding tumour cells.
Tumour blood flow changes induced by application of
electric pulses and electrochemotherapy
We have already demonstrated in previous studies that electric
pulses and electrochemotherapy significantly reduce the blood
flow of the treated tumours (Sersa et al, 1999a,b). In this study, we
used two new approaches to further evaluate this effect. We used
power Doppler ultrasonographic imaging to assess the gross
tumour blood flow changes and LDF to monitor local micro-
vascular blood flow in the tissue. The application of eight electric
pulses to the tumours reduced the blood flow of the tumours
immediately after their application. Power Doppler ultrasono-
graphic imaging showed immediate abrogation of blood flow in
the vessels supplying the tumour, with restoration of blood flow
within 48h after application of electric pulses alone (Figure 4).
The same time course of the effect was observed after elec-
trochemotherapy of the tumours. However, at 48h after electro-
chemotherapy, a reduced tumour blood flow was still observed
after electrochemotherapy, contrary to electric pulses alone. Blood
flow in tumours in the control group and in tumours treated with
BLM only did not change during the observation period.
We were further able to follow the exact profile of micro-
circulatory changes by means of LDF after application of electric
pulses to the tumours or electrochemotherapy in a small volume
of tumour tissue. Figure 5A shows a highly reproducible example
of an extremely rapid decline in microcirculatory perfusion, which
starts as soon as the first pulse is delivered and continues until the
maximum reduction is obtained, which can occur as soon as 10s
after application of the first pulse. This figure also demonstrates
various movement artefacts present in raw laser Doppler signal
(owing to respiration, electrode manipulation and delivery of
electric pulses) and thus the need for filtering of such a signal
before any signal analysis.
Figure 5B and C show average changes in perfusion of tumours
in the four experimental groups. The rapid and abrupt initial
decrease in perfusion of tumours after application of electric
pulses and electrochemotherapy-treated tumours was followed by
a gradual but only partial reperfusion of the tumours. This partial
reperfusion peaked approximately 10–15min after delivery of
electric pulses and did not continue afterwards. On the contrary,
the injection of BLM or physiological saline (control) produced no
significant changes during the observation period. The four
experimental groups started to differ significantly as soon as 30s
after application of electric pulses and remained significantly
different until the end of observation (Po0.001 for all time
instants after time zero in Figure 5B). The differences were highly
significant (Po0.001) between control and BLM alone compared
to the group of tumours that was exposed to electric pulses or the
electrochemotherapy group. Differences between the groups before
and at time zero in Figure 5B were not statistically significant
(P40.05). It was also interesting to note that the two groups
involving the use of BLM (BLM alone and electrochemotherapy)
developed higher blood flow levels after treatment than the
corresponding two groups without BLM (control and application
of electric pulses, respectively), which can be observed in
Figure 5B. However, even though this difference was consistent,
it was not statistically significant (P40.05).
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Figure 4 Representative power Doppler ultrasonographic images of tumours (delineated with white lines A and B) treated by bleomycin, electric pulses
or electrochemotherapy at various time points post-treatment.
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staining of the tumours with similar vascular effects as observed
with other methods of measurement (Figure 6). An immediate
reduction was observed in tumour perfusion after application of
electric pulses and electrochemotherapy with reduction of tumour
perfusion to 10% of the value in control tumours. Approximately
0.5h later, the tumours started to reperfuse in both groups; in the
tumours treated by electrochemotherapy, the reperfusion levelled
at B1h after the treatment and stayed at B20% up to 48h after
the treatment, whereas the tumours treated with application of
electric pulses continued to reperfuse and reached normal values
between 24 and 48h.
Tumour hypoxia induced by application of electric pulses
and electrochemotherapy
Blood flow measurements showed that there is an immediate
reduction of tumour blood flow after the application of electric
pulses and electrochemotherapy. Owing to the effect of applied
electric pulses on the vascular supply of the tumours, the extent of
hypoxic regions in the tumours as a consequence of reduced
tumour blood flow was determined.
Tumour sections were immunohistochemically stained for
protein adduct of reductively activated pimonidazole. Positive
staining was found in the cytoplasm of tumour cells and some
positive nuclei of tumour cells were also determined. As
pimonidazole is known to be preferentially bound by hypoxic
tumour cells, the detection of pimonidazole adducts using
monoclonal antibodies can serve as a method for measuring
tumour hypoxia. In most control tumours, discrete foci of
pimonidazole positivity were found. In BLM-treated tumours, a
rim of positive cells was found mainly around the necrotic area. In
electric pulses and in the electrochemotherapy-treated group of
tumours, reticular staining patterns were observed at some
distance from blood vessels, with some diffuse pimonidazole-
positive area. In some slides from the electrochemotherapy-treated
group of tumours, the endothelial cells of blood vessels were also
positive. The tumour cells around these pimonidazole-labelled
vessels did not show pimonidazole immunoreactivity (Figure 7).
The percentage of pimonidazole-positive tumour areas in viable
tumour tissue was determined and the results are presented in
Figure 8. Both in the group of tumours treated with electric pulses
and in those treated with electrochemotherapy, the onset of
tumour hypoxia was instant, reaching its peak at 2h and lasting up
to 8h after treatment. After the application of electric pulses, the
recovery to the pretreatment level lasted 14h, whereas the recovery
to pretreatment level after electrochemotherapy lasted 24h. From
24 to 48h after treatment, the level of tumour hypoxia was the
same in all experimental groups.
Tissue oxygenation changes induced by application of
electric pulses and electrochemotherapy
Partial pressure of oxygen was measured in animals treated with
BLM and with the application of electric pulses to the tumours and
electrochemotherapy, using EPR oximetry. In the same animals,
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Figure 5 Blood flow changes after different treatments assessed by
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scatter (nonsignificant) of values at time zero was of transient nature and
was a result of movement artefacts caused by manipulation of the
electrodes. Note different time scale.
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Figure 6 Time course of changes in tumour perfusion in untreated
tumours, and after treatment of tumours with bleomycin, application of
electric pulses or electrochemotherapy. Symbols indicate AM (arithmetic
mean)±s.e. of at least three mice per point.
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sthe pO2 values were recorded in the tumours that were treated, as
well as in the subcutaneous tissue that was not treated and was
located on the contralateral side from the tumour. The pO2 values
in the subcutaneous tissue were higher than those measured in the
tumours. Furthermore, the pO2 values in the centre of the tumour
were lower than those in the periphery of the tumours (Table 2).
All treatments, even BLM alone, had a rapid effect on pO2 with
maximal reduction of tissue oxygenation occurring within 2h after
the treatment (Table 2). We also followed the time course of pO2
changes relative to the pretreatment values of the specific
treatment (Figure 9). The systemic injection of BLM induced
some reduction in subcutaneous tissue (for 12%) and in tumour
oxygenation (for 28%), with steady recovery to the pretreatment
values within 48h. The application of electric pulses to the
tumours induced instantaneous reduction of pO2 to 38% of the
pretreatment level, with steady recovery to pretreatment level
within 8h. Electrochemotherapy of tumours had a similar but
more profound effect on the tumour oxygenation than the
application of electric pulses alone. The onset and the degree of
pO2 reduction in tumours after treatment with electrochemo-
therapy was immediate, and within 2h it was same as with the
application of electric pulses; however, the recovery of tumours the
oxygenation was much slower, returning to the pretreatment level
with a delay as long as 2 days. Application of electric pulses and
electrochemotherapy also had some effect on oxygenation of
subcutaneous tissue that was distant from the application of
electric pulses. Electrochemotherapy in subcutaneous tissue
induced bigger pO2 reduction (for 30%) than the application of
electric pulses alone (for 8%).
DISCUSSION
The results of our study demonstrate that besides its direct
cytotoxic effect on tumour cells, electrochemotherapy with BLM
also has a vascular disrupting action by causing a rapid shutdown
of tumour blood flow, leading to reduced tumour oxygenation,
increased tumour hypoxia and extensive tumour cell necrosis.
Furthermore, owing to the blood vessel changes caused by a high
concentration of BLM in the endothelial cells of tumour blood
vessels, this therapy has prolonged vascular disrupting effects
leading to pronounced antitumour effectiveness. The mathematical
model of electric field distribution in and the around tumour blood
vessel supports the physiological data by demonstrating that
endothelial cells are exposed to a B40% higher electric field
compared to the tumour tissue farther from the blood vessel.
Electroporation of tissues in vivo has great potential as a drug
delivery system, as it is universal and easily applicable, also in
humans. It can be used for the delivery of various molecules that
have a hampered access to cytosol, such as some widely used
chemotherapeutic drugs like BLM and cisplatin, or naked DNA
(Cemazar et al, 2006; Sersa, 2006a). Several studies have indicated
that electroporation of tissues, including tumours, induces
intracellular accumulation of BLM or cisplatin, in the latter case
Control Bleomycin 
Electric pulses  Electrochemotherapy 
Figure 7 Representative tumour sections 90min after treatment with bleomycin, application of electric pulses or electrochemotherapy. Brown regions
are the cells stained with pimonidazole, a marker of tumour hypoxia. Note marked differences in the extent of hypoxic regions between groups without
application of electric pulses (control and bleomycin) and those with the application of electric pulses (electric pulses and electrochemotherapy).
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Figure 8 Time course of changes in tumour hypoxia in untreated
control tumours, and after treatment of tumours with bleomycin,
application of electric pulses alone or electrochemotherapy. Excised
tumours were stained with pimonidazole, and percentage of pimonidazole
positive tumour areas were determined. AM (arithmetic mean)±s.e. of at
least three mice per point.
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salso leading to an approximately twofold increase of binding of
cisplatin to DNA (Belehradek et al, 1994; Cemazar et al, 1999). This
enables increased cytotoxicity of the drugs such as BLM or
cisplatin, particularly in the cells that are exposed to electric fields
that cause their electroporation. Therefore, the antitumour
effectiveness of electrochemotherapy was so far attributed
predominantly to direct cytotoxicity of the delivered chemo-
therapeutic drugs to tumour cells, as a predominant population of
cells in the tumours.
However, the application of electric pulses to the tissues, either
muscles or tumours, induces vascular effects that need to be
studied for possible interaction with other electroporation-based
therapies such as gene electrotransfer. It has been shown already
that the application of electric pulses to the tumours induces
reduction of tumour blood flow that is profound but transient.
The tumour vascular disrupting effects of electroporation were
demonstrated both by rubidium extraction technique and Patent
blue staining (Sersa et al, 1999a). This phenomenon was
considered as beneficial, both for electrochemotherapy and gene
electrotransfer. A consequence of reduced blood flow in the tissue
is entrapment of the molecules delivered before electroporation of
the tissue, providing longer exposure of the cells to the cytotoxic
drugs, by preventing washout of the molecules from the tissue.
Furthermore, in clinical cases it was observed that during
electrochemotherapy, immediately after the application of electric
pulses, the bleeding of haemorrhagic tumour nodules has stopped
(Gehl and Geertsen, 2006). In our present study, we provide further
evidence on previous observations about the tumour vascular
disrupting action of electroporation. We demonstrated the instant
abrogation of tumour blood flow after the applied electric pulses
on the tumour, and recovery of tumour blood flow within 24h.
The instantaneous effect on blood flow was demonstrated by LDF
and also by power Doppler ultrasonographic imaging as well as
Patent blue staining. All approaches also demonstrated the
recovery of tumour blood flow. Power Doppler ultrasonographic
imaging using contrast agents is a noninvasive technique that is
routinely used in a clinical setting and is therefore a very suitable
method to assess the changes in tumour blood flow. In our study,
we demonstrated the usefulness of this noninvasive technique for
monitoring changes in blood flow in real time. Therefore, this
technique could be used for planning of combined treatment
approaches where antivascular therapies are combined with other
therapies targeting hypoxic cells or therapies that should be
applied at the time of maximal reperfusion after the first treatment
(Shaked and Kerbel, 2007). Laser Doppler flowmetry demonstrated
that vascular shutdown occurred very rapidly, which cannot be
attributed to the death of endothelial cells and thus confirm the
results of our in vitro study on adherent endothelial cell monolayer
(Kanthou et al, 2006). Specifically, we demonstrated that
the electroporation-induced vascular effects can be attributed to
the rapid disruption of microfilament and microtubule cytoskeletal
networks that paralleled an increase in endothelial monolayer
permeability (Kanthou et al, 2006). This may lead to increased
liquid extravasation and, as a consequence of the increased
interstitial fluid pressure, also to the collapse in blood vessel
structures. Vasoconstriction due to the effects on smooth muscle
cells in tumour blood vessels is less likely, owing to its lack in
tumour vessels, as opposed to blood vessels in normal tissues,
where this kind of effects was already described (Gehl et al, 2002).
Several two- and three-dimensional numerical calculations have
demonstrated that an adequate distribution of electric field above
the threshold value for electroporation is important for effective
electrochemotherapy (Miklavcic et al, 1998, 2006). By applying
adequate electric pulses with suitable amplitude, most of the tissue
positioned between the electrodes should be electroporated.
Therefore, stromal cells as well as cell-forming vascular network
are also exposed to an electric field that can have electroporative
effect. To validate whether endothelial cells in the lining of small
tumour vessels are exposed to an electric field that can increase
their membrane permeability, a mathematical model was then
used. The model predicted that endothelial cells lining the tumour
blood vessels are even exposed to B40% higher electric field than
the surrounding tumour cells. This exposure to a high electric field
indicates that tumour endothelial cells are a valid target for
electroporation and electrochemotherapy. The application of
electric pulses to the tumour, therefore, has a selective, more
pronounced, effect on endothelial cells compared to tumour cells.
In addition to that, by electrochemotherapy, during electropora-
tion, endothelial cells are exposed to a relatively higher
concentration of the chemotherapeutic drug (BLM or cisplatin)
compared to tumour cells. Therefore, it can be presumed that
electrochemotherapy has a cytotoxic effect on endothelial cells in
the treated tumours, which may lead to a prolonged reduction of
tumour blood flow. This prolonged reduction in tumour blood
flow (vascular disrupting action) has been demonstrated in our
previous studies on electrochemotherapy with BLM and cisplatin
(Sersa et al, 1999a, 2002), as well as in the present study by power
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Figure 9 Time course of changes in partial pressure of oxygen (pO2)
measured by EPR oximetry in tumours and subcutaneous tissue distant
from the tumours, where electric pulses were not applied. The data were
combined for tumour centre and tumour periphery. Animals were treated
intravenously with bleomycin (1mgkg
 1) and 3min later eight electric
pulses were applied to the tumours (1040V, 100ms, 1Hz). Symbols
indicate AM (arithmetic mean)±s.e. of six mice per point.
Table 2 Partial pressure of oxygen (pO2) measured by EPR oximetry in SA-1 tumours and subcutis before the treatment of tumours and 2h after
treatment by electric pulses, bleomycin and electrochemotherapy
Pretreatment values Bleomycin
a Electric pulses
b Electrochemotherapy
c
Tissue/therapy (mmHg, AM±s.e.) (mmHg, AM±s.e.) (mmHg, AM±s.e.) (mmHg, AM±s.e.)
Subcutis 8.37±0.05 7.35±0.09
d 7.66±0.08
d 5.90±0.17
d
Tumour periphery 7.33±0.09 4.93±0.19
d 2.16±0.07
d 2.11±0.13
d
Tumour centre 5.35±0.05 4.58±0.07
d 2.68±0.14
d 1.39±0.12
d
EPR¼electron paramagnetic resonance.
aBleomycin injected intravenously (1mgkg
 1).
bApplication of electric pulses to the tumour (8 pulses, 1040V, 100ms, 1Hz).
cElectrochemotherapy: application of electric pulses to the tumour 3min after intravenous injection of bleomycin.
dP-values (o0.05) for different treatments vs normal values.
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sDoppler US imaging and Patent blue staining. The measurement of
hypoxia in tumours and partial pressure of oxygen do not entirely
follow the measurement of reduction of blood flow. The reduction
of partial pressure of oxygen was instantaneous but with quick
recovery to the pretreatment level within 8h after application of
electric pulses or 48h after electrochemotherapy of the tumours.
These results on tissue oxygenation correlated well with the
observed percentage of the pimonidazole-positive area, but not
with the reduction of tumour blood flow as demonstrated by
power Doppler ultrasonography and Patent blue staining. We
demonstrated that the pimonidazole-positive area increased to
35% within 1h after treatment, with recovery to control values
within 12h after application of electric pulses, whereas tumour
blood flow did not recover during the observation period. The
reason for that can be that the percentage of pimonidazole-positive
area did not increase after electrochemotherapy because in the
viable area that remained after therapy, blood flow was restored
and the pimonidazole-positive areas were not evaluated in the
necrotic areas. Another reason for lower pimonidazole-positive
areas can also be ascribed to the fact that the pimonidazole uptake
into tumour tissue could be prevented if some parts of the tumours
are not perfused at all (owing to the normal fluctuation of tumour
blood flow), and this could result in falsely negative areas, despite
being hypoxic owing to the treatment. Furthermore, the dis-
crepancy between the oxygenation measurements obtained by EPR
oximetry and blood flow reduction measured by power Doppler
sonography and Patent blue technique could be due to the
differences in the sample volume of the techniques. Specifically,
with power Doppler sonography, the whole tumour is assessed,
whereas with EPR oximetry, pO2 is measured only in the region in
contact with the probe that comprises only B0.5mm
3. As the
probes were inserted mainly in the periphery of the tumours,
which is part of the tumour that recovers after the treatment with
vascular disruption agents, quicker the restoration of partial
oxygen pressure compared to tumour blood flow could result from
the differences in measurement between the techniques. Never-
theless, the results of partial pressure of oxygen indicated that
restoration of oxygen supply in the region of interest after
electrochemotherapy is much slower than after electroporation
only. This may indicate that many cells undergo cell death, which
may take up to 24h. Furthermore, histological analysis of the
tumours indicated that the extent of tumour necrosis after
electroporation of tumours paralleled the extent of tumour
necrosis after electrochemotherapy up to 24h after treatment
and that only thereafter is there an increase in the extent of tumour
necrosis by electrochemotherapy. This may indicate, on a dual
effect, the immediate vascular disrupting action of electroporation
(increase in vascular permeability due to the disruption of
endothelial cytoskeleton and endothelial cell swelling) and delayed
effect due to the exposure of these cells to a high concentration of
BLM causing endothelial cell death as observed in histological
specimens. The first phenomenon is present up to 8–12h after
electroporation of the tissue and is due to disruption of endothelial
cell lining in tumour vessels leading to some extent of tumour cell
death present up to 24h, but with quick recovery without
significant antitumour effect. The second phenomenon is due to
endothelial cell death caused by electrochemotherapy that in
addition to the vascular disrupting action of electroporation
induces a prolonged shutdown of tumour blood flow and
consequently a cascade of tumour cell death in the surrounding
tissue that becomes evident at longer times after therapy. Further
support for this second phenomenon is the observation that
predominantly central tumour necrosis after electrochemotherapy
was observed, which is characteristic for vascular disrupting
agents.
Electroporation compared to other vascular disrupting agents
such as CA-4-P and DMXAA, which have specific effects on
tumour blood vessels as opposed to normal blood vessels, is not
specific and selectivity is achieved by the local application of
electric pulses to the tumours. The vascular disrupting effects
of vascular disrupting agents on tumour endothelial cells involve
the rapid reorganisation of the actin cytoskeleton, which is
mediated by the disruption of the tubulin cytoskeleton for CA-4-
P, but not DMXAA (Tozer et al, 2005). The signalling pathways
associated with CA-4-P and their effects on vascular permeability
involve the activation of small GTPase Rho and Rho kinase
(Kanthou and Tozer, 2002). The activation of Rho proteins
necessitates their translocation and association with membrane
components (Bokoch et al, 1994). In the case of electroporation,
actin as well as microtubule cytoskeleton is disrupted as a
consequence of the applied electric field; however, disruption by
electroporation appears to uncouple Rho and inactivate Rho
kinases. It is likely that electroporation inactivates Rho by
preventing its association with the cell membrane (Kanthou
et al, 2006).
Electroporation, similar to vascular disrupting agents, induces a
very rapid and significant reduction in tumour blood flow, which
can be detected already within a minute after the application of the
treatment. The proposed mechanism for rapid tumour vascular
shutdown after treatment with CA-4-P or DMXAA involves the
disruption of the cytoskeleton of endothelial cells, leading to cell
shape changes and an increase in the permeability of the cell
monolayer. This would increase vascular resistance to blood flow.
Apoptosis of endothelial cells might also contribute to vascular
shutdown. Other contributing factors are platelet activation and
serotonin release leading to active vasoconstriction. The protein
leakage due to the increased tumour vascular permeability would
lead to oedema and an increase in tumour interstitial pressure
further leading to vascular collapse. In addition, as the blood flow
slows down, red cells stack up causing an increase in viscous
resistance and slowing the blood flow by positive mechanisms. The
consequence of this is the appearance of central necrosis with a
viable peripheral rim of tumour cells, leading to rapid repopula-
tion of tumours and the consequent failure to achieve significant
tumour growth delay (Tozer et al, 2005). Major vascular disrupting
agents that have been tested in clinical phase I studies include
CA-4-P, DMXAA, ZD6126, AVE8062 and ABT-751 (Hinnen and
Eskens, 2007; Patterson and Rustin, 2007). The combination of
vascular disrupting agents with other treatment modalities, such as
radiotherapy or chemotherapy, leads to increased antitumour
effect of these combined treatments (Tozer et al, 2005; Patterson
and Rustin, 2007). In the case of electrochemotherapy, electro-
poration is combined with chemotherapy. This treatment in a
single application thus combines the immediate vascular disrup-
ting action of electroporation with delayed endothelial cell death
caused presumably by a high chemotherapeutic drug concentra-
tion in the cytosol of endothelial cells. Both these effects, in
addition to direct tumour cell killing by electrochemotherapy,
contribute to the high antitumour effectiveness of electrochemo-
therapy.
In conclusion, in this study, we provide evidence that
electrochemotherapy, in addition to direct cytotoxic effect on
tumour cells, has a vascular disrupting action. The vascular
disrupting action is dual, namely the effect of application of
electric pulses to the tumours that induce a rapid shutdown of
tumour blood flow that recovers within 24h and the continuation
of the vascular disrupting effect of electrochemotherapy, pre-
dominantly through its cytotoxic effect on endothelial cells.
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